Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study is testing how well a combination of drugs called isatuximab, carfilzomib, pomalidomide, and dexamethasone works to treat a type of cancer called multiple myeloma. Isatuximab may stop cancer cells from growing, carfilzomib may block proteins that help cancer cells grow, pomalidomide may make the cancer grow slower, and dexamethasone may help the other drugs work better. All of these drugs together may be able to kill more cancer cells.
This study is testing how well a combination of drugs called isatuximab, carfilzomib, pomalidomide, and dexamethasone works to treat a type of cancer called multiple myeloma. Isatuximab may stop cancer cells from growing, carfilzomib may block proteins that help cancer cells grow, pomalidomide may make the cancer grow slower, and dexamethasone may help the other drugs work better. All of these drugs together may be able to kill more cancer cells.
*Third Opinion AI Generated Synopsis
Trial Summary
This phase II trial studies the effect of isatuximab, carfilzomib, pomalidomide, and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Isatuximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Carfilzomib may stop the growth of cancer cells by blocking some of the proteins needed for cell growth. Pomalidomide may help shrink or slow the growth of mutliple myeloma. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving isatuximab, carfilzomib, pomalidomide, and dexamethasone may kill more cancer cells.
This phase II trial studies the effect of isatuximab, carfilzomib, pomalidomide, and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Isatuximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Carfilzomib may stop the growth of cancer cells by blocking some of the proteins needed for cell growth. Pomalidomide may help shrink or slow the growth of mutliple myeloma. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving isatuximab, carfilzomib, pomalidomide, and dexamethasone may kill more cancer cells.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: